No Long-Term Benefit From Intravitreal Bevacizumab in Neovascular Glaucoma: StudyNo Long-Term Benefit From Intravitreal Bevacizumab in Neovascular Glaucoma: Study

Intravitreal bevacizumab does not alter the long-term outcomes of neovascular glaucoma (NVG), so panretinal photocoagulation (PRP) should remain the mainstay of treatment, according to a retrospective study. Reuters Health Information
Source: Medscape Ophthalmology Headlines - Category: Opthalmology Tags: Ophthalmology News Source Type: news